Rivaroxaban zur Therapie bei tiefer Venenthrombose gleich gut wie herkömmliche Anti-koagulation mit Heparin und Vitamin-K-Antagonist

Steurer, Johann
August 2011
Praxis (16618157);8/10/2011, Vol. 100 Issue 16, p989
Academic Journal
No abstract available.


Related Articles

  • Value of anticoagulants in the treatment of pulmonary embolism: a discussion paper. Egermayer, Paul // Journal of the Royal Society of Medicine;Sep1981, Vol. 74 Issue 9, p675 

    The article discusses the benefits of anticoagulants in the treatment of pulmonary embolism. The effects of heparin, the mainstay of treatment, and its hazards in treating pulmonary embolism are discussed. It was found that anticoagulants such as warfarin prevents the recurrence of pulmonary...

  • Nouveaux anticoagulants. Mise au point et enjeux en chirurgie orale. Lansonneur, C�dric; Guillou, Pauline; Hacquard, Aur�lie; Devisse, Manon; Lelievre, Julie; Le Gal, Gr�goire; Boisram�-Gastrin, Sylvie // M�decine Buccale Chirurgie Buccale;2013, Vol. 19 Issue 1, p11 

    Heparins, either unfractionated or lowmolecular- weight (UFH and LMWHs), and vitamin K antagonists (VKA) are currently the anticoagulants of choice for the prevention of postoperative venous thromboembolism (VTE) and for the treatment of acute venous and arterial thromboembolism. Heparins are...

  • Use of Enoxaparin for Anticoagulation Therapy. Sadovsky, Richard // American Family Physician;2/1/2000, Vol. 61 Issue 3, p842 

    Discusses research on the use of enoxaparin in anticoagulation therapy. Reference to a study by J. M. Spandorfer, et al., from the August 15, 1999 issue of the `American Journal of Cardiology'; Effectiveness of heparin in anticoagulation therapy; Assessment on patients who are receiving...

  • STUDY SHOWS LIFE-SAVING BENEFITS OF "CLOT-BUSTING" DRUGS.  // Heart Advisor;Sep2014, Vol. 17 Issue 9, p2 

    The article focuses on the study published in the "Journal of the American Medical Association" which shows that clot-busting medications can reduce deaths while treating patients with sudden-onset pulmonary embolism.

  • Management of pulmonary embolism. Ruckley, C.V. // British Medical Journal (Clinical Research Edition);9/25/1982, Vol. 285 Issue 6345, p831 

    Focuses on the management of pulmonary embolism. Administration on the use of anticoagulant drugs; Provision of intravenous fluids to support right ventricular output and pulmonary blood flow; Importance of resuscitation after the direct treatment.

  • LMWHs cost-effectively treat DVT with low side effects. McCue // Managed Healthcare;Dec99, Vol. 9 Issue 12, p38 

    Relates the need for health maintenance organizations in the United States to include low-molecular weight heparins (LMWH) in their anticoagulation services. Effectiveness of LMWH in treating deep-vein thrombosis (DVT); Reduction in the costs of treating DVT due to the advent of LMWH; Side...

  • Venous thromboembolism: treatment strategies. Turpie, Alexander G G; Chin, Bernard S P; Lip, Gregory Y H // BMJ: British Medical Journal (International Edition);10/26/2002, Vol. 325 Issue 7370, p948 

    Discusses the treatment of pulmonary embolism and deep vein thrombosis. The use of similar drugs and physical methods; The use of unfractionated heparin and low molecular weight heparin; The use of coumarins; Thrombolytic therapy; Treatment during pregnancy.

  • The anticoagulants market. Melnikova, Irena // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p353 

    The article focuses on the various antithrombotic drugs, including anticoagulants, antiplatelet agents and direct thrombolytics, being used for both the prevention and the acute treatment of thrombosis. The anticoagulants currently available include vitamin K antagonists, heparin and warfarin....

  • Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism. Couturaud, Francis; Sanchez, Olivier; Pernod, Gilles; Mismetti, Patrick; Jego, Patrick; Duhamel, Elisabeth; Provost, Karine; dit Sollier, Claire Bal; Presles, Emilie; Castellant, Philippe; Parent, Florence; Salaun, Pierre-Yves; Bressollette, Luc; Nonent, Michel; Lorillon, Philippe; Girard, Philippe; Lacut, Karine; Guégan, Marie; Bosson, Jean-Luc; Laporte, Silvy // JAMA: Journal of the American Medical Association;7/7/2015, Vol. 314 Issue 1, p31 

    IMPORTANCE The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain. OBJECTIVES To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics